Skip to main content

Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.

Journal articles  - Journal Article
Buckner, CD; Fefer, A; Bensinger, WI; Storb, R; Durie, BG; Appelbaum, FR; Petersen, FB; Weiden, P; Clift, RA; Sanders, JE
Published in: Eur J Haematol Suppl
1989

28 patients with plasma cell malignancies received marrow transplants from identical twins (N = 8), HLA-identical family members (N = 15), HLA partially-matched relatives (N = 3) or cryopreserved autologous marrow (N = 2). Treatment regimens included cyclophosphamide (CY) and total body irradiation (TBI) for 15 patients and busulphan (BU) and CY for 13 patients. 3 of 8 twins are alive, 2 without disease at 24 and 34 months, and 1 is alive and well at 116 months without evidence of disease except for at small residual monoclonal protein spike. 12 of the 18 allografted patients died of transplant-related causes and 2 died of progressive disease. 4 of 18 allograft recipients are alive; 2 are free of disease at 16 and 15 months, 1 is alive at 6 months without disease except for persistent monoclonal Kappa protein. 1 patient is alive with residual marrow involvement and a persistent IGA lambda monoclonal protein at 7 months. 1 of the 2 autograft recipients is alive 2 months after transplant and is not yet evaluable for tumor response and the other patient died early of transplant-related complications. Both CY + TBI and BU + CY resulted in remissions in patients with advanced plasma cell malignancies. However, the optimal treatment regimen and timing of transplantation remain to be determined.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Haematol Suppl

DOI

ISSN

0902-4506

Publication Date

1989

Volume

51

Start / End Page

186 / 190

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Leukemia, Plasma Cell
  • Humans
  • Evaluation Studies as Topic
  • Diseases in Twins
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Buckner, C. D., Fefer, A., Bensinger, W. I., Storb, R., Durie, B. G., Appelbaum, F. R., … Sanders, J. E. (1989). Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl, 51, 186–190. https://doi.org/10.1111/j.1600-0609.1989.tb01515.x
Buckner, C. D., A. Fefer, W. I. Bensinger, R. Storb, B. G. Durie, F. R. Appelbaum, F. B. Petersen, P. Weiden, R. A. Clift, and J. E. Sanders. “Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.” Eur J Haematol Suppl 51 (1989): 186–90. https://doi.org/10.1111/j.1600-0609.1989.tb01515.x.
Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl. 1989;51:186–90.
Buckner, C. D., et al. “Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.” Eur J Haematol Suppl, vol. 51, 1989, pp. 186–90. Pubmed, doi:10.1111/j.1600-0609.1989.tb01515.x.
Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, Petersen FB, Weiden P, Clift RA, Sanders JE. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl. 1989;51:186–190.

Published In

Eur J Haematol Suppl

DOI

ISSN

0902-4506

Publication Date

1989

Volume

51

Start / End Page

186 / 190

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Leukemia, Plasma Cell
  • Humans
  • Evaluation Studies as Topic
  • Diseases in Twins
  • Combined Modality Therapy